Date:11/14/2007

istory of ovarian, uterine or breast cancer; a history of polyps, especially large adenomatous polyps; a history of inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease; a high fat, low-fiber diet; a sedentary life-style; obesity; cigarette smoking, both currently and in the past; heavy alcohol use; and diabetes. Other possible personal risk factors for colorectal cancer include a history of working the night-shift several nights a week for at least 15 years and previous radiation treatment for prostate cancer. Familial and hereditary risk factors include: having a close relative who had colorectal cancer before age 60; family history of polyposis syndromes and hereditary non-polyposis syndromes; African-American background; and Ashkenazi Jewish background. Frequent testing with colonoscopy, sigmoidoscopy, double contrast barium enemas and fecal occult blood tests are performed in these high-and increased risk populations. The age at which this intensive screening should begin depends on the actual risk factors. For example, it should begin at puberty for those with a history of familial adenomatous polyposis, at 12 -15 years after the onset of left- sided inflammatory bowel disease and, if an immediate relative has had colorectal cancer, at 10 years before the age that the relative was diagnosed.

Failure to diagnose colorectal cancer before it has spread can have disastrous consequences. The 5 year relative survival rates are 89.8% for localized disease, 67.7% for regional disease, and 10.3% for metastatic disease. Even persons who know that they are at high risk and increased risk for colorectal cancer, however, are often non-compliant or poorly compliant with screening recommendations because they perceive the tests to be embarrassing, unpleasant and time-consuming. In addition, many people who are at higher-than-average risk do not know that they are particularly at risk nor do their physicians always inform them of their risk. F
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals